352030-17-2

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 7149-75-9 3-methyl-4-chloroaniline 

Downstream Products

• 492430-08-7 ethyl 2-[2-[(tert-butoxycarbonyl)amino]-5-chloro-4-methylphenyl]-2-oxoacetate 
• 352030-18-3 C₁₆H₁₄ClNO₃ 

Relevant academic research and scientific papers

ACTIVATORS OF HIV LATENCY

The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating HIV expression in latently infected cells. Further still, the invention relates to pharmaceutical compositions comprising the novel compounds in combination with anti-HIV therapy compounds and their use in treating HIV infection in both animals and humans. The invention further provides means for preparing the compounds.

Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use

The invention relates to compounds of formula: and also to the salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, with affinity for and selectivity towards the arginine-vasopressin V1b receptors and/or for the ocytocin receptors and, furthermore, for certain compounds, affinity for the V1a receptors. The invention also relates to the process for preparing them, to the intermediate compounds of formula (IV) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for preparing medicinal products.